|
Price : 5slide for 600 $
CDA2 Human, colon and rectal cancer | |||||||
Age | Sex | Site | Pathology | TNM | Stage | Months* | |
1 | 40 | F | sigmoid | adenocarcinoma, W/D | T3N2M0 | ⅢC | . |
2 | 65 | F | cecum | Mucinous adenocarcinoma | T3N2M0 | ⅢC | . |
3 | 56 | M | ascending | adenocarcinoma, M/D | T4N1M0 | ⅢB | . |
4 | 65 | F | sigmoid | adenocarcinoma, W/D | T3N0M0 | ⅡA | . |
5 | 62 | M | ascending | adenocarcinoma, M/D | T3N0M0 | ⅡA | . |
6 | 57 | F | sigmoid | adenocarcinoma, W/D | T3N1M0 | ⅢB | . |
7 | 78 | M | sigmoid | adenocarcinoma, W/D | T3N1M0 | ⅢB | . |
8 | 45 | M | rectum | adenocarcinoma, W/D | T3N1M0 | ⅢB | . |
9 | 65 | M | ascending | adenocarcinoma, W/D | T3N1M0 | ⅢB | . |
10 | 61 | M | transverse | Mucinous adenocarcinoma | T3N0M0 | ⅡA | . |
11 | 52 | M | rectum | adenocarcinoma, M/D | T3N0M1 | Ⅳ | . |
12 | 52 | F | sigmoid | adenocarcinoma, M/D | T2N2M0 | ⅢC | . |
13 | 47 | F | cecum | adenocarcinoma, M/D | T3N0M0 | ⅡA | . |
14 | 63 | F | descending | adenocarcinoma, M/D | T3N1M0 | ⅢB | . |
15 | 53 | M | cecum | adenocarcinoma, M/D | T3N1M0 | ⅢB | . |
16 | 53 | F | transverse | adenocarcinoma, W/D | T3N0M0 | ⅡA | . |
17 | 64 | M | sigmoid | adenocarcinoma, M/D | T3N1M0 | ⅢB | . |
18 | 59 | M | sigmoid | adenocarcinoma, M/D | T4N0M0 | ⅡB | . |
19 | 57 | M | ascending | adenocarcinoma, M/D | T4N0M0 | ⅡB | . |
20 | 59 | M | ascending | adenocarcinoma, M/D | T3N0M0 | ⅡA | . |
21 | 35 | F | ascending | Mucinous adenocarcinoma | T3N0M0 | ⅡA | . |
22 | 49 | F | ascending | adenocarcinoma, M/D | T3N2M0 | ⅢB | . |
23 | 76 | M | sigmoid | adenocarcinoma, M/D | T3N1M1 | Ⅳ | . |
24 | 74 | M | ascending | adenocarcinoma, M/D | T3N0M0 | ⅡA | . |
25 | 60 | F | rectum | adenocarcinoma, M/D | T4N0M0 | ⅡB | . |
26 | 62 | M | sigmoid | adenocarcinoma, M/D | T3N0M0 | ⅡA | . |
27 | 57 | M | sigmoid | adenocarcinoma, M/D | T3N0M0 | ⅡA | . |
28 | 56 | F | sigmoid | adenocarcinoma, M/D | T3N2M1 | Ⅳ | . |
29 | 75 | F | rectum | adenocarcinoma, W/D | T3N1M0 | ⅢB | . |
30 | 58 | M | rectum | adenocarcinoma, M/D | T3N0MX | ⅡA | . |
31 | 62 | M | rectum | adenocarcinoma, M/D | T4N1M0 | ⅢB | . |
32 | 65 | F | cecum | Mucinous adenocarcinoma | T3N2M0 | ⅢC | . |
33 | 36 | M | transverse | adenocarcinoma, M/D | T3N2M0 | ⅢC | . |
34 | . | F | descending | adenocarcinoma, W/D | T4N1M1 | Ⅳ | . |
35 | 46 | F | ascending | adenocarcinoma, P/D | T3N2MX | ⅢC | . |
36 | 42 | M | transverse | adenocarcinoma, M/D | T3N2M0 | ⅢC | . |
37 | 62 | M | sigmoid | adenocarcinoma, M/D | T3N2M1 | Ⅳ | . |
38 | 41 | F | sigmoid | adenocarcinoma, W/D | T4N2M1 | Ⅳ | . |
39 | 51 | M | rectum | adenocarcinoma, M/D | T4N2M0 | ⅢC | . |
40 | 47 | F | sigmoid | adenocarcinoma, M/D | T4N1M1 | Ⅳ | . |
41 | 66 | M | lung | metastatic adenocarcinoma from #31 | . | . | 42 |
42 | 65 | F | lymph node | metastatic carcinoma from #32 | . | . | 0 |
43 | 36 | M | lymph node | metastatic carcinoma from #33 | . | . | 0 |
44 | . | F | ovary | metastatic adenocarcinoma from #34 | . | . | 0 |
45 | 46 | F | lymph node | metastatic carcinoma from #35 | . | . | 0 |
46 | 42 | M | lymph node | metastatic carcinoma from #36 | . | . | 0 |
47 | 62 | M | lymph node | metastatic carcinoma from #37 | . | . | 0 |
48 | 41 | F | ovary | metastatic adenocarcinoma from #38 | . | . | 0 |
49 | 52 | M | lung | metastatic adenocarcinoma from #39 | . | . | 17 |
50 | 47 | F | ovary | metastatic adenocarcinoma from #40 | . | . | 0 |
51 | 40 | F | sigmoid | normal colon (adjacent to cancer, match of #1) | . | . | . |
52 | 68 | M | sigmoid | normal colon (adjacent to cancer, match of #2) | . | . | . |
53 | 45 | M | rectum | normal colon (adjacent to cancer, match of #8) | . | . | . |
54 | 62 | M | sigmoid | normal colon (adjacent to cancer, match of #26) | . | . | . |
55 | 42 | M | transverse | normal colon (adjacent to cancer, match of #36) | . | . | . |
56 | 49 | F | ascending | normal colon (apart from cancer, match of #22) | . | . | . |
57 | 76 | M | sigmoid | normal colon (apart from cancer, match of #23) | . | . | . |
58 | 36 | M | transverse | normal colon (apart from cancer, match of #33) | . | . | . |
59 | 62 | M | sigmoid | normal colon (apart from cancer, match of #37) | . | . | . |
60 | carbon | ||||||
*: interval between primary and metastatic cancer | |||||||
W/D, well differentiated; M/D, moderately differentiated; P/D, poorly differentiated | |||||||
TNM Classification : Colon and Rectum carcinoma (AJCC 6th Edition) |
General Information of the Tissue Array Slide :
Applications
- Immunohistochemistry
- In situ hybridization, RNA or DNA
- Fluorescent in situ hybridization (FISH)
- In situ PCR, RNA or DNA
- TUNEL for apoptosis (Recommended procedures in www.tissue-array.com -> protocol)
Storage and stability
- Individual slide is paraffin-coated and put in an air-tight pack with inert gas.
- Tissue array slides are shipped in room temperature.
- If the slides are stored in 4 degree, they are good up to one year.
How processed
- Tissues were initially fixed with formalin except for some of the animal tissues.
- Then, dehydrated with gradient ethanol; typically 1 hour each progressive steps; 70%, 90%, 95%, 99%, 100% x 3 times.
- Cleared by xylene, three changes for 1 hour each.
- Infiltrated with 60°C paraffin, three changes for 1 hour each
- Microtoming in 4 µm thickness and put on silane coating slide from Muto Pure Chemicals (Japan)
Before use
- Dry slides for 1 hour in a oven at 60 degree.
- Dewax slides in xylene for 4 minutes x 5 times
- Hydrate slides in 100%, 95% and 75% ethanol for 3 minutes x 2 times each.
- Immerse slides in tap water for 5 minutes
Slide orientation
- In most of the slides with 59 or 60 cores, the orientation is as below unless indicated otherwise. #60 location is usually filled with carbon for orientation.
Shaded area |
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 |
11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 |
21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 |
31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 |
41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 |
51 | 52 | 53 | 54 | 55 | 56 | 57 | 58 | 59 | 60 |